Used as an anticoagulant to reduce the risk of blood clots, particularly in adult patients hospitalized for acute illness who are at risk for thromboembolic events. It is especially considered for extended-duration prophylaxis in those with multiple risk factors for venous thromboembolism. Its once-daily oral dosing offers convenience in inpatient and post-discharge settings. Betrixaban inhibits Factor Xa in the coagulation cascade, helping prevent deep vein thrombosis and pulmonary embolism without requiring routine laboratory monitoring.